EUVIMEDEUVIMED entdecken
Crossref

Supramolecular Prodrug Hydrogel for One‐Week Protection Against Thrombosis

Wenjing Zhang, Xue Tian, Sheng Xu, Bin Wu, Tianyue Jiang iD

Small · 2026

DOI: 10.1002/smll.202500193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2026. Verfasst von Wenjing Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, 211816, China. Hauptthemen laut MEDLINE: Prodrugs, Thrombosis, Hydrogels. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In clinical anticoagulant therapy, the drug Bivalirudin (Biva) presents a lower incidence of adverse events and more predictable pharmacokinetics in comparison to heparin. However, its short half‐life of ≈20 min leads to poor patient compliance and increased medical burden. Here, a long‐acting anticoagulant hydrogel based on Biva for antithrombotic treatment is described. The fusion peptide ( d ‐RADA)8‐B that integrates Biva, a D‐type self‐assembly motif, and an activated factor X (FXa)‐responsive motif exhibits both supramolecular reservoir and prodrug‐like properties. After subcutaneous injection, the anticoagulant peptide forms a semi‐solid depot with protease‐degradation resistance and slowly disassembles to release prodrug ( d ‐RADA)8‐B into the bloodstream. The circulating prodrug acts as an inert sentinel, which can be activated to release Biva to inhibit thrombus formation when exposed to the thrombus‐related protease FXa. One week after the administration of ( d ‐RADA)8‐B, significant embolism suppression is observed in animal models of carotid artery thrombosis and pulmonary embolism without increasing hemorrhagic side effects. This study demonstrates a concise strategy to engineer a supramolecular anticoagulant hydrogel with long‐term, high drug loading, and on‐demand antithrombotic activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsThrombosisHydrogelsAnimalsHirudinsPeptide FragmentsAnticoagulantsRecombinant ProteinsMiceHumans

Stichwörter der Autor:innen

anticoagulantbivalirudinlong‐termprodrugsupramolecular hydrogel

Substanzen

ProdrugsHydrogelsHirudinsbivalirudinPeptide FragmentsAnticoagulantsRecombinant Proteins

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, 211816, China.
  • School of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing, 211816, China.

ORCID-Profile: Tianyue Jiang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, W., Tian, X., Xu, S., Wu, B., & Jiang, T. (2026). Supramolecular Prodrug Hydrogel for One‐Week Protection Against Thrombosis. Small. https://doi.org/10.1002/smll.202500193

Vancouver

Zhang W, Tian X, Xu S, Wu B, Jiang T. Supramolecular Prodrug Hydrogel for One‐Week Protection Against Thrombosis. Small. 2026. doi:10.1002/smll.202500193

BibTeX
@article{Zhang2026,
  author = {Zhang, Wenjing and Tian, Xue and Xu, Sheng and Wu, Bin and Jiang, Tianyue},
  title = {Supramolecular Prodrug Hydrogel for One‐Week Protection Against Thrombosis},
  journal = {Small},
  year = {2026},
  doi = {10.1002/smll.202500193}
}
Kostenlos starten →